Ganesh Sambasivam, Ph.D.
CSO & Co-Founder, Anthem Biosciences India
Preclinical Outsourcing to India
The outsourcing segment is witnessing rapid changes with respect to the nature of work outsourced and the location. Cost is the major driver but other considerations such as infrastructure and government policies can also be important drivers for decision making. The last couple of years have been a trying time for all CROs. The global economic meltdown has hit research budgets especially hard. The new challenges facing Contract Research Organizations call for a radically revised approach and a new model that would push the boundaries of this business further and would blur the line between client and vendor further. I believe the term Contract Research Organization (CRO), is a misnomer to begin with (often confused with Clinical Research Organization), has now morphed into a new type of company viz Contract Innovation Services (CIS). Clients are no longer just happy to outsource odds and ends of the development piece but are looking to their vendors for a massive amount of innovation input. This input is increasingly across both the chemistry and discovery domains. This new paradigm calls for CIS companies to develop new platforms, create intellectual propertythat is of service to clients andinnovate processes to meet new found customer expectations.
Ashok Pandey, Ph.D.
Scientist F & Head, Biotechnology Division, National Institute for Interdisciplinary Science and Technology-CSIR), Thiruvananthapuram, India
Alternative renewable resources: Issues and perspectives for India – the case of transport fuels
With the increase in the urbanization way of life and also more and more dependence on materialistic life, there is substantial growing demand for the energy. The science and technological policy of the India has looked several avenues to fulfill this demand through alternative resources such as solar energy, wind energy, tidal energy, bioenergy, etc. The demand for the transport sector is largely met through the import (~70%). Biofuels, in particular bioethanol from lignocellulosic biomass offer attractive possibilities in this regard.
The sugar platform which generates ethanol is considered to be the most valuable solution to the transport fuel demand. Bioethanol can be generated from grains as well as from lignocellulosic plant material by their saccharification to sugars and subsequent fermentation of the sugars to produce ethanol. Bio-ethanol as a transportation fuel is attractive since it is more energy efficient than gasoline and produces less emissions. The benefits of developing biomass to ethanol technology(s) include: increased national energy security, reduction in GHG emissions, use of renewable resources, economic benefits and creation of employment and the foundation of a carbohydrate based chemical industry. However, the utilization of lignocellulosic biomass for fuel generation has not been given the sort of attention it ought to receive. It is known that the technology for ethanol production from biomass has to evolve greatly for an economical commercial scale utilization of the renewable biomass resources. Biomass requires extensive processing involving multiple steps for hydrolysis and fermentation of the raw material for producing ethanol. Feed stock availability, pretreatment, saccharification, fermentation and ethanol recovery are all factors which influence the production of ethanol and which needs R&D efforts for overall improvement of the production economics.
Bioconversion of lignocellulosic biomass (LB) can contribute significantly to the production of organic chemicals also. LB is also considered to be the only foreseeable source of energy. LB is mainly composed of (dry wt basis): cellulose, 40-60; hemicellulose, 20-40; and lignin, 10-25%. Most efficient method of biomass hydrolysis is through enzymatic saccharification5 using cellulases and hemicellulases. Fungal cellulases (FCs) have proved to be a better candidate than other microbial cellulases, with their secreted free cellulase complexes comprising all three components of cellulase [endoglucanases, exoglucanases and cellobiases (glucosidases).
The Centre for Biofuels at NIIST, Trivandrum, India aims ultimately to develop technologies and processes which will address the nation’s need for making fuel ethanol from the renewable resource: biomass. It is proposed to direct R&D activities at the major requirements of a biomass-ethanol technology, which include production of cellulases, hydrolysis of biomass, and ethanol fermentation. Viable technologies for each of these processes will contribute to the overall process development for fuel alcohol production from cheap and renewable biomass resources.
The lecture would present perspectives on bioethanol from lignocellulosic feedstocks.
References
- Biofuels- Alternative Feedstocks and Conversion Processes, Editors- Ashok Pandey, C Larroche, SC Ricke, CG Dussap & E Gnansounou, Academic Press, Elsevier Inc; San Diego, USA, p629 (2011) ISBN: 978-0-12-385099-7
- Handbook of Plant-Based Biofuels, Editor- Ashok Pandey, CRC Press, Francis & Taylors, Boca Raton, USA, p 297 (2008) ISBN 978-q-5602-2175-3
- Biofuels II, Special issue of Journal of Scientific & Industrial Research, Guest Editors- E Gnansounou, C Larroche and Ashok Pandey, 67(11), 837-1040 (2008) ISSN: 0022-4456
- Biofuels, Special issue of Journal of Scientific & Industrial Research, Guest Editors- C Larroche and Ashok Pandey, 64(11), 797-988 (2005) ISSN: 0022-4456
Jaydeep Unni, Ph.D.
Sr. Project Manager, Robert Bosch Healthcare Systems, Palo Alto, CA
Remote Patient Monitoring – Challenges and Opportunities
Remote Patient Monitoring (RPM) is gaining importance and acceptance with rising number of chronic disease conditions and with increase in the aging population. As instances of Heart diseases, Diabetes etc are increasing the demand for these technologies are increasing. RPM devices typically collect patient vital sign data and in some case also patient responses to health related questions. Thus collected data is then transmitted through various modalities (wireless/Bluetooth/cellular) to Hospitals/Doctor’s office for clinical evaluation. With these solutions Doctors are able to access patient’s vital data ‘any time any where’ thus enabling them to intervene on a timely and effective manner. For older adult population chronic disease management, post-acute care management and safety monitoring are areas were RPM finds application. That said, there are significant challenges in adoption of Remote Patient Monitoring including patient willingness and compliance for adoption, affordability, availability of simpler/smarter technology to mention a few. But experts contend that if implemented correctly Remote Patient Monitoring can contain healthcare expenditure by reducing avoidable hospitalization while greatly improving quality of care.
Arathy R and Binoy B Nair
PC based heart sound monitoring system
Heart diseases caused by disorders of the heart and blood vessels, are world’s largest killers. Early detection and monitoring of heart abnormalities is essential for diagnosis and effective treatment of heart diseases. Severalmethodologies are used for screening and diagnosing heart diseases. They are auscultation, electrocardiogram (ECG), echo-cardiogram, ultrasound etc. The effectiveness and applicability of all these diagnostic methods are highly dependent on the equipment cost and size as well as skill of the physician. This paper presents the design and development of a low cost portable wireless/tubeless digital stethoscope which can be used by the physician for monitoring the patient from a distance. The stethoscope system interfaces to a PC and is also capable of analyzing the heart sounds and identifying abnormalities in the heart sound and its classification. Storage of heart sound for later analysis is also possible.This advanced functionality increases the physician’s diagnostic capability, and such a PCG is not still available in most hospitals. Acoustic stethoscope can be changed into a digital stethoscope by inserting an electric capacity microphone into its diaphragm (Wang, Chen and Samjin, 2009).
Bodo Eickhoff, Ph.D.
Senior Vice-President, Head of Sales and Marketing for Roche Applied Science, Germany
New paths for treatment of complex diseases: target combinatorial drug therapy
Several types of diseases show a complex pathogenesis and require targeted as well as combinatorial drug treatment. A classical example, Tuberculosis, was thought for decades to be managable by triple therapy, however now requiring new therapeutic approaches due to multi drug resistant strains. HIV and AIDS can only be kept under control by combinations of specific, virus-protein targeted drugs, requiring constant monitoring of resistance patterns and modulation of drug combinations during life-long therapy. As a third example, Cancer in all its different variations, requires detailled molecular understanding to enable targeted therapy. New technologies provide more and in depths molecular insights into pathomechanisms and resulting treatment options. However, is there an alternative way to approach complex diseases by holistic models? Can restoring of apoptosis-capabilities of transformed cells be an example of such an alternative path? How do we in future adress major unresolved topics like increasing drug resistance in bacterial infections, lack of anti-viral drugs, treatment of parasite diseases like Malaria, and newly emerging infectious diseases in research and fast translation of these results into diagnosis and treatment?